SCHEMBL4725591

SCHEMBL4725591

CCC(C(N)=O)c1cccc2c3ccccc3n(CC)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.46
LMNA P02545 4/20 0.46
MAPK1 P28482 3/20 0.46
POLB P06746 2/20 0.46
NPY5R Q15761 1/20 0.43
ALDH1A1 P00352 6/20 0.42
HTT P42858 3/20 0.41
MAPT P10636 6/20 0.41
KMT2A Q03164 3/20 0.40
HPGD P15428 3/20 0.40
MEN1 O00255 2/20 0.40
HBB P68871 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TSPO P30536 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
PKM P14618 1/20 0.39
RCE1 Q9Y256 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7838579 0.76 KDM4E (0.51) KDM4ELMNAMAPK1POLBNPY5R
SCHEMBL3255854 0.74 ALDH1A1 (0.48) KDM4EALDH1A1HTTHPGD
SCHEMBL29003631 0.72 KDM4E (0.62) KDM4ELMNAPOLBALDH1A1HTT
SCHEMBL16487273 0.72 NPSR1 (0.49) KDM4ELMNAMAPK1POLBNPY5R
SCHEMBL31294735 0.71 KDM4E (0.41) KDM4EALDH1A1KMT2AMEN1HSD17B10
SCHEMBL14208786 0.71 ALDH1A1 (0.59) KDM4ELMNAMAPK1POLBALDH1A1
SCHEMBL3511142 0.70 KDM4E (0.56) KDM4ELMNAMAPK1POLBNPY5R
SCHEMBL30412874 0.70 KDM4E (0.56) KDM4ELMNAMAPK1POLBNPY5R
SCHEMBL29139893 0.70 ALDH1A1 (0.50) KDM4ELMNAMAPK1POLBNPY5R
SCHEMBL15466547 0.70 ALDH1A1 (0.55) KDM4ELMNAMAPK1POLBNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008021745-A2 HEPATITIS C VIRUS ENTRY INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2008-02-21 WO disclosed